drugset / Trial / NCT05130567

A Study of LP-128 Capsules in Healthy Subjects

NCT05130567 ↗

Phase 1 Active not recruiting 104 enrolled Guangzhou Lupeng Pharmaceutical Company LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects

Timeline

Start
2021-11-19
Primary completion
2026-09-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LP-128 Unknown — Oral